Fixx Pharmaceuticals, inc

View Our Newsroom

Fixx Pharmaceuticals Looks to Cure Hemophilia with Gene Editing

Industry: Healthcare

Fixx Pharmaceuticals was founded by Jesse John Francis Clark who was born with severe Hemophilia.

San Francisco, CA (PRUnderground) August 27th, 2020

​Fixx Pharmaceuticals Inc. is pleased to announce the launch of its biotechnology business operations in Las Vegas, Nevada and San Francisco, California.

The company is focused on developing a cure for Hemophilia through the use of CRISPR gene editing. There are currently 20,000 people in the U.S. who suffer from hemophilia and 400,000 globally.

“We are looking to commercialize a product as soon as possible,” says Jesse John Francis Clark, founder of Fixx. “We are going to develop a product that is more cost-effective for payers. We’re looking to keep it under $2 million per patient” he said, saying that the overall cost of care of hemophilia patients will decrease. “If we are successful in developing a commercialized product, we are looking at upwards of $40 billion in sales from the U.S. market alone. I think our investors will be happy with that” says Clark.

Jesse John Francis Clark is an internationally known professional, entrepreneur, and passionate advocate for people living with Hemophilia and related bleeding disorders. Born with severe Hemophilia, Clark founded HemoAware Corporation in 2018, a non-profit organization dedicated to enriching the lives of people with inherited bleeding disorders through advocacy, education, and technology.

For more information about Fixx Pharmaceuticals Inc., please visit https://www.fixxpharma.com.

email us here

DISCLAIMER: The news site hosting this press release is not associated with ​Fixx Pharmaceuticals Inc. or Jesse John Francis Clark. It is merely publishing a press release announcement submitted by a company, without any stated or implied endorsement of the information, person, product or service. Please do your own due diligence.

About Fixx Pharmaceuticals, inc

Fixx Pharmaceuticals’ mission is to develop targeted therapies to support patients suffering from bleeding disorders, specifically Hemophilia. The company was founded in 2020 and is located in Las Vegas and California.

Print Friendly, PDF & Email

Press Contact

Name
Jesse Clark
Phone
888-321-3499
Email
Contact Us
Website
https://www.fixxpharma.com

Image Gallery

Video